Skip to content

Role of home telemonitoring of lung function using the forced oscillation technique (FOT) in asthma during stable treatment.

Role of home telemonitoring of lung function using the forced oscillation technique in predicting exacerbations and control among moderate-severe asthmatics during stable treatment: a pragmatic, observational study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12618000837224
Acronym
ASTHMA-HOMEMON
Enrollment
8
Registered
2018-05-18
Start date
2018-06-06
Completion date
2021-06-01
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Clinical management of asthma involves tailoring medication to minimise the frequency and intensity of symptoms and prevent exacerbation's. However, management is currently based on subjective patient recall of symptoms, rather than objective and personalised measures of current status and predictors of future risk of exacerbation's. A potential solution may be offered by daily home monitoring using Forced Oscillation Technique (FOT), which patients can measure unsupervised at home due to its ease of use compared to peak flow or spirometry. We have shown potential clinical utility of advanced analyses to study the day­-to-­day variability in lung function in asthma in a series of retrospective studies, including the ability to predict future exacerbation's within a month in an individual. This project aims to adapt such analyses to FOT data as the basis of a home telemonitoring system, and initiate a prospective study investigating the potential benefit of long-­term FOT home monitoring in Australian patients with both well­-controlled and uncontrolled asthma. We aim to show that FOT variability (i) predicts occurrence of exacerbation's, (ii) is related to asthma control, and (iii) is sensitive to treatment changes. We will demonstrate this by studying moderate-to-severe asthma patients in a pragmatic, observational study in well­-controlled asthma patients who are being considered for reduction of their inhaled corticosteroid treatment dose. Treatment is initiated by the physician according to Australian guidelines independent of participation in the study, and we will study these relationships regardless of the nature of treatment. We will monitor unsupervised FOT measurements and symptoms over a period of 10-­24 weeks. Data will be uploaded automatically via mobile internet to encrypted servers and regularly checked for quality. We will also monitor exacerbation's and asthma control via weekly telephone interviews and questionnaires. From these results, we eventually hope to develop an automated alert system which can signal to the patient whether or not they are about to deteriorate and to initiate self-treatment, enabling them to gain control of their disease.

Interventions

In a pragmatic, observational study, we will evaluate the ability of day-to-day variations in lung function measured by the forced oscillation technique (FOT), to predict occurrence of exacerbations (primary outcome) and changes in symptom control (secondary outcome) in asthma, during a period of stable treatment unless otherwise clinically-indicated by their physician. Potential patients are identified during routine clinic visits (treated as Visit 1) or recruited from the community based on t

In a pragmatic, observational study, we will evaluate the ability of day-to-day variations in lung function measured by the forced oscillation technique (FOT), to predict occurrence of exacerbations (primary outcome) and changes in symptom control (secondary outcome) in asthma, during a period of stable treatment unless otherwise clinically-indicated by their physician. Potential patients are identified during routine clinic visits (treated as Visit 1) or recruited from the community based on their clinical status, i.e. poorly-controlled symptoms despite being on maximal ICS treatment dose, and not being considered at the point of screening for down- or up-titration of their treatment by their treating physician within the next 6 months. Patients who are eligible for the study will be asked if they are willing to participate in home monitoring, and have their baseline health status, symptoms (ACQ-5) and standard respiratory function (spirometry and lung volumes) data collected as part of their standard clinical assessment. Patients willing to participate in the study will have a FOT device installed in their homes by a study investigator (a respiratory researcher familiar with FOT), who will train them to make unsupervised FOT self-measurements during a 30-45 minute visit. Participants will be monitored for an initial (approximate) 8-week baseline period during which existing treatment will be unchanged unless clinically warranted. At approximately the 8-week (Visit 2) and/or 16-week (Visit 3) marks, their clinical status will be evaluated, either via their last clinic visits or an appointment, to assess whether treatment changes are warranted. Monitoring will cover a total period of approximately 24 weeks (8 weeks of baseline period + 16 weeks prediction phase). During this time, any treatment decisions/changes will be made solely by the treating physician based on the patient’s clinical need. Throughout the entire study period, patients will self-record symptoms and FOT once daily in the morning, followed by a PEF measurement, before taking their maintenance treatment. Patients will also have weekly telephone interviews where questionnaire data (ACQ), symptoms and exacerbations will be captured. Details of measurements performed during home monitoring can be found below. Treatment Changes Should a treating physician deem that a change in treatment is warranted during any phase, e.g. due to loss of control or exacerbations, patients will not need to be withdrawn, but will continue daily monitoring as per usual. FOT Measurements FOT home monitoring devices (Resmon Pro DIARY, Restech srl, Milan, Italy) will be set up at the patient’s home at enrolment. The technical specifications for the device have been previously published [Dellaca et al, Physiol Meas (2010) 31:N11–N24]. During measurement, a loudspeaker generates 5-11-19 Hz forced oscillations delivered to the airway opening via an antibacterial filter/mouthpiece assembly. The resulting airway opening pressure and flow are measured and used to calculate respiratory resistance. These can be further partitioned into an inspiratory and expiratory component. Patients will be instructed to make a 1- to 2-min measurement (for a minimum of 10 technically acceptable breaths) each day during normal breathing whilst seated, wearing a nose clip and with cheeks supported. De-identified FOT data will be uploaded daily via the 4G mobile internet network to encrypted servers, where they will be checked for quality by a research assistant. PEF Measurements Following FOT, patients will also monitor their PEF using a digital spirometer using standardised protocol, i.e. highest of 3 blows. Patients who currently make PEF measurements will be asked to use the digital spirometer, and they will be shown how to extract the results for their normal monitoring. Patients who have never made PEF measurements before will be instructed on how to do them during the home visit. Symptom and Exacerbation Measurements Daily symptoms will be entered into an electronic diary prior to the FOT measurement via the same device interface. We will use an adaptation of symptom diary used in a recently published trial [Virchow et al, Jama (2016) 315:1715-25], from which the definition of moderate exacerbations was derived. In addition, study personnel will contact the patient weekly to record treatment changes, symptoms (ACQ-5), medications and asthma-related healthcare utilisation, to capture changes in asthma control and/or exacerbations. During this time, patients will continue to see their usual healthcare provider when necessary.

Sponsors

Sydney Medical School, University of Sydney
Lead SponsorUniversity

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Inclusion Criteria: • above 18 years of age, • diagnosis of asthma, confirmed by written report from a physician, and • receiving maintenance asthma treatment at at least Step 4 (on moderate to high dose of ICS (budesonide >500 mcg/day or fluticasone propionate >200 mcg/day or equivalent and LABA treatment) of Australian guidelines, and • ACQ-5 score >=1.5, indicating suboptimal asthma symptom control. All patients will be eligible if they are taking maximal inhaled therapy (high dose ICS/LABA with or without other add-on therapy) and have at least one of the following additional risk factors for poor asthma outcomes or exacerbation's, i.e.: at least one severe exacerbation in the past 12 months, low FEV1 (<60% predicted), obesity (BMI >=30), and in addition, the treating physician considers that there is no immediate indication for stepping up treatment. For example, this decision may be made by the treating physician if the risks of further stepping up treatment outweigh the potential benefit, if alternative non-biologic therapies have already been tried, or if the patient does not satisfy PBS criteria for a biological therapy.

Exclusion criteria

• any other confounding major disease or condition as deemed appropriate by investigator, determined by review of medical history and/or patient reported medical history, and • impaired ability to understand instructions or perform FOT unsupervised.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026